<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Eumycetoma
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Eumycetoma
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Eumycetoma
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Beatriz Bustamante, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Pablo E Campos, MD, MPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Carol A Kauffman, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Elinor L Baron, MD, DTMH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 06, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mycetoma (also termed ‘Madura foot’) is a chronic skin and soft tissue infection resulting in a mass, sinus formation, and discharge with grains (which contain colonies of the causative organism); it extends to adjacent tissues in some cases [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         Mycetoma can be caused by fungi (eumycetoma) or bacteria (actinomycetoma, most commonly actinomyces, streptomyces, or
         <em>
          Nocardia
         </em>
         ). Issues related to eumycetoma will be reviewed here; issues related to actinomycetoma are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5513.html" rel="external">
          "Treatment of nocardiosis", section on 'Mycetoma'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5515.html" rel="external">
          "Nocardia infections: Epidemiology, clinical manifestations, and diagnosis", section on 'Skin'
         </a>
         .)
        </p>
        <p>
         Eumycetoma ("mycotic mycetoma") usually occurs on the foot but other parts of the body can also be affected; The causative microorganisms likely gain entry via a thorn prick or other skin lesion. The disease typically occurs in resource-limited settings and is on the World Health Organization's list of neglected diseases [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most cases of eumycetoma occur among individuals living in resource-limited countries in tropical and subtropical regions, although cases have been reported worldwide (including in temperate regions). The true prevalence is not known since it is not a reportable disease. Most published eumycetoma cases come from Africa and India, while actinomycetoma cases seem to be most common in Latin America [
         <a href="#rid1">
          1-6
         </a>
         ].
        </p>
        <p>
         Eumycetoma typically affects healthy adult men such as field laborers or farmers who work in rural areas and have frequent exposure to soil. The mean age is 33 (range, 8 to 68 years); pediatric cases are rare. The male to female ratio is about 3:1 to 5:1.
        </p>
        <p>
         Eumycetoma among animals is rare but has been reported in horses, water buffalo, and dogs. There are no known cases of zoonotic or laboratory acquisition of eumycetomas nor has person-to-person transmission been described.
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The pathogenesis of eumycetoma infection is not fully understood. Many individuals are exposed to eumycetoma agents but only a few develop the disease. Risk factors appear to include environmental exposure to pathogenic organisms and genetic predisposition to infection.
        </p>
        <p>
         Eumycetoma begins with traumatic inoculation of the organism into cutaneous and/or subcutaneous tissues. Trauma may be minor (due to thorns, splinters, or other objects), and patients may not recall a specific injury [
         <a href="#rid7">
          7-9
         </a>
         ].
        </p>
        <p>
         In general, infection remains localized. Grains (colonies of infecting organisms, with melanin or other substances) are formed in infected tissues; free filaments do not develop. The grains are partially broken down via a neutrophil-mediated inflammatory reaction; their remains perpetuate an inflammatory response. An epithelioid granuloma develops via recruitment of macrophages, which form multinucleated giant cells and clear dead neutrophils and grain fragments [
         <a href="#rid10">
          10
         </a>
         ]. The role of melanin production is not fully understood; it has been linked to virulence and pathogenicity. Melanization appears to protect the organism from strong oxidants and azole drugs in vitro [
         <a href="#rid11">
          11
         </a>
         ]. The host produces cytokines and enzymes, which have been shown to degrade the chitin contained in grains of
         <em>
          Madurella mycetomatis
         </em>
         , the most common cause of eumycetoma [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
         Genetic predisposition to development of eumycetoma or actinomycetoma may be an important factor in pathogenesis. In endemic areas, many individuals have antibodies to
         <em>
          M. mycetomatis
         </em>
         . It has been postulated that some individuals lack sufficient neutrophil function to clear the organism and thus develop disease [
         <a href="#rid13">
          13
         </a>
         ]. In addition, polymorphism in the gene for chitotriosidase that results in enzyme inactivity has been associated with increased risk for mycetoma [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
         Although eumycetoma frequently develops in the absence of immunosuppression, a number of cases have been reported in immunocompromised patients. These include one case due to
         <em>
          Exophiala jeanselmei
         </em>
         in a patient with an idiopathic CD4+ T cell lymphocytopenia and another case due to
         <em>
          Madurella
         </em>
         spp in a patient with acute myeloid leukemia undergoing chemotherapy [
         <a href="#rid14">
          14,15
         </a>
         ]. Eumycetoma has also been described in solid organ transplant recipients; most had a good outcome with antifungal therapy and/or surgical management despite immunosuppressive therapy [
         <a href="#rid16">
          16-19
         </a>
         ]. One series described both eumycetoma and actinomycetoma in association with diabetes (9 out of 26 cases) [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
         The role of the immune response in the setting of eumycetoma is not fully understood. Some studies have described a reduction in cell-mediated immune response among patients with eumycetoma or actinomycetoma [
         <a href="#rid21">
          21,22
         </a>
         ]; another failed to demonstrate any immune alteration [
         <a href="#rid23">
          23
         </a>
         ]. The small number of participants in these studies and the mixing of eumycetoma and actinomycetoma cases preclude drawing definitive conclusions.
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          MICROBIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Organisms capable of causing eumycetoma are distributed worldwide and include at least 44 hyaline and pigmented species of molds  (
         <a class="graphic graphic_table graphicRef58060" href="/z/d/graphic/58060.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid24">
          24-36
         </a>
         ]. Microbiologic diagnosis and characterization of the exact organism causing eumycetoma is difficult, and the necessary identification tools are often not available in endemic areas.
        </p>
        <p>
         The predominant pathogen is
         <em>
          M. mycetomatis
         </em>
         , which, along with
         <em>
          Trematosphaeria grisea
         </em>
         (formerly
         <em>
          Madurella grisea
         </em>
         ),
         <em>
          Falciformispora senegalensis
         </em>
         (formerly
         <em>
          Leptosphaeria senegalensis
         </em>
         ), and
         <em>
          Scedosporium apiospermum
         </em>
         species complex (formerly
         <em>
          Pseudallescheria boydii
         </em>
         /
         <em>
          S. apiospermum
         </em>
         ) are responsible for more than 90 percent of reported eumycetoma cases worldwide  (
         <a class="graphic graphic_figure graphicRef61250" href="/z/d/graphic/61250.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p>
         Grains contain aggregated colonies of the causative microorganisms encapsulated in a cement-like material, with melanin or other substances; they may be observed macroscopically or microscopically. Some species produce grains with thickened fungal cell walls; these include
         <em>
          S. apiospermum
         </em>
         species complex,
         <em>
          Fusarium
         </em>
         spp,
         <em>
          Acremonium killiense
         </em>
         , and
         <em>
          M. mycetomatis
         </em>
         [
         <a href="#rid38">
          38
         </a>
         ]. Cell-wall thickening may be an important factor in the difficulties associated with obtaining cultures from grains.
        </p>
        <p>
         Traditionally, black-grain eumycetomas caused by
         <em>
          Madurella
         </em>
         have been attributed to
         <em>
          M. mycetomatis
         </em>
         as this was the only accepted species in the genus beside
         <em>
          T. grisea
         </em>
         [
         <a href="#rid39">
          39
         </a>
         ]. However, use of molecular techniques has identified three additional species of
         <em>
          Madurella
         </em>
         :
         <em>
          Madurella fahalii
         </em>
         ,
         <em>
          Madurella pseudomycetomatis
         </em>
         , and
         <em>
          Madurella tropicana
         </em>
         [
         <a href="#rid26">
          26,40
         </a>
         ].
         <em>
          M. mycetomatis
         </em>
         remains the prevalent species causing mycetoma worldwide; the others are rare.
         <em>
          M. fahalii
         </em>
         has been reported from Sudan, Mali, Saudi Arabia, and Canada [
         <a href="#rid26">
          26,39
         </a>
         ], and
         <em>
          M. tropicana
         </em>
         has been reported in Sudan [
         <a href="#rid26">
          26,39
         </a>
         ].
        </p>
        <p>
         The local prevalence of specific pathogens is determined by ecologic conditions including temperature, rainfall, type of soil, prevalent vegetation, and pollution [
         <a href="#rid41">
          41
         </a>
         ].
         <em>
          M. mycetomatis
         </em>
         is common in arid zones [
         <a href="#rid42">
          42
         </a>
         ], whereas
         <em>
          S. apiospermum
         </em>
         species complex is common in temperate rainy areas [
         <a href="#rid20">
          20,43
         </a>
         ].
         <em>
          S. apiospermum
         </em>
         species complex are also found more frequently in nitrogen-rich environments with organic pollution from human, poultry, and cattle manure [
         <a href="#rid44">
          44
         </a>
         ]. In Africa,
         <em>
          M. mycetomatis
         </em>
         and
         <em>
          F. senegalensis
         </em>
         are the most common pathogens;
         <em>
          T. grisea
         </em>
         and
         <em>
          S. apiospermum
         </em>
         species complex are less frequent pathogens. In South America,
         <em>
          T. grisea
         </em>
         is the most prevalent pathogen, followed by
         <em>
          M. mycetomatis
         </em>
         and
         <em>
          S. apiospermum
         </em>
         species complex. In North America,
         <em>
          S. apiospermum
         </em>
         species complex are the most prevalent pathogens, followed by
         <em>
          T. grisea
         </em>
         . Studies using molecular techniques demonstrate that
         <em>
          M. pseudomycetomatis
         </em>
         could be the dominant
         <em>
          Madurella
         </em>
         species in South and Central America [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
         Soil is the natural reservoir for most of these agents.
         <em>
          M. mycetomatis
         </em>
         ,
         <em>
          T. grisea
         </em>
         ,
         <em>
          S. apiospermum
         </em>
         species complex,
         <em>
          Phialophora verrucosa
         </em>
         , and
         <em>
          Neotestudina
         </em>
         <em>
          rosatii
         </em>
         have been isolated from soil samples [
         <a href="#rid46">
          46,47
         </a>
         ]. It has been demonstrated that thorns serve as mechanical vectors only after they are contaminated with soil. This was illustrated in an evaluation of thorns in the Senegal River region; culprit organisms were demonstrated on fallen Acacia thorns but not on green thorns (eg, thorns not contaminated with soil) [
         <a href="#rid48">
          48,49
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition and incubation period
         </strong>
         − Eumycetoma is a chronic subcutaneous mycotic infection of the skin and soft tissue; in some cases, it extends to adjacent tissues. Uncovered areas that are exposed to trauma and soil are most often affected [
         <a href="#rid50">
          50
         </a>
         ]. The incubation period between inoculation and clinical manifestations is uncertain, and many patients may not recall a specific predisposing injury.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Involved sites
         </strong>
         − Eumycetoma most frequently involves the feet, followed by legs and hands (80, 7, and 6 percent, respectively, in one study) [
         <a href="#rid51">
          51
         </a>
         ]. Workers who carry vegetable matter over exposed areas of the back or abdomen are susceptible to eumycetoma in these regions; direct spread to the vertebral bodies and the spinal cord can occur [
         <a href="#rid1">
          1,52
         </a>
         ]. Less frequent sites include buttocks, forearms, the groin/perineum, head/neck, and testicles [
         <a href="#rid7">
          7,20,51,53-56
         </a>
         ]. The occurrence of multiple eumycetomas is rare and should prompt consideration of alternative diagnoses [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical findings
         </strong>
         − Mycetoma (eumycetoma or actinomycetoma) may present with a characteristic triad of tumor (painless firm subcutaneous mass), sinus tracts, and discharge-containing macroscopic or microscopic grains  (
         <a class="graphic graphic_picture graphicRef115024" href="/z/d/graphic/115024.html" rel="external">
          picture 1
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Initially, lesions are painless and commence as slowly growing indurated subcutaneous nodules  (
         <a class="graphic graphic_picture graphicRef67717" href="/z/d/graphic/67717.html" rel="external">
          picture 2
         </a>
         and
         <a class="graphic graphic_picture graphicRef59276" href="/z/d/graphic/59276.html" rel="external">
          picture 3
         </a>
         ). Extension of lesions occurs due to nodular swelling and coalescence, forming large tumors that evolve into necrotic abscesses and draining sinus tracts, which may produce a discharge that contains grains  (
         <a class="graphic graphic_picture graphicRef69384" href="/z/d/graphic/69384.html" rel="external">
          picture 4
         </a>
         and
         <a class="graphic graphic_picture graphicRef54129" href="/z/d/graphic/54129.html" rel="external">
          picture 5
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The clinical appearance may underestimate the extent of involvement; undetected subcutaneous tracts can extend beyond the limits of the mass. (See
         <a class="local">
          'Grain identification and fungal culture'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Depth of involvement
         </strong>
         − Eumycetomas are usually confined to subcutaneous tissues but can involve fascia, bone, and regional lymph nodes via contiguous dissemination [
         <a href="#rid58">
          58
         </a>
         ]. Hematogenous spread may also be possible but is rare [
         <a href="#rid59">
          59
         </a>
         ]. Bone involvement is more frequent in the setting of longstanding lesions [
         <a href="#rid7">
          7,60
         </a>
         ]. Lesions in areas with thin subcutaneous tissue (eg, feet, hands, and skull) are more likely to progress to bone involvement. Bone invasion can result in cavities filled with grains that contain fibrous tissue, which provides stability; therefore, pathologic fractures are uncommon. Bone involvement portends a poor prognosis and requires a longer course of therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Complications
         </strong>
         − Eumycetoma lesions may evolve over months, years, or decades. In the absence of treatment, they may become deforming and disabling tumors  (
         <a class="graphic graphic_picture graphicRef54129" href="/z/d/graphic/54129.html" rel="external">
          picture 5
         </a>
         ). Complications include fibrosis, ankylosis, and lymphedema caused by lymphatic obstruction. Other rare complications have been observed; these include massive destruction of a joint, pulmonary eumycetoma secondary to a subcutaneous lesion, and bronchopleural cutaneous fistula [
         <a href="#rid61">
          61-64
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Nerves and tendons are rarely affected until late in the disease; although the lesion may be tender, pain is not a typical feature. The presence of pain is often associated with secondary bacterial infection (commonly caused by
         <em>
          Staphylococcus aureus
         </em>
         ); in one series that included 98 cases of mycetoma, of which 90 percent were eumycetoma, this complication was observed in 66 percent of cases [
         <a href="#rid65">
          65
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          DIAGNOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H1518968660">
         <span class="h2">
          General approach
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical diagnosis
         </strong>
         – In endemic areas with limited diagnostic tools, the diagnosis of mycetoma is often made clinically; a clinical diagnosis may be established in patients with the characteristic triad of tumor, sinus tracts, and discharge-containing grains. Presence of black grains indicate a fungal etiology (establishing a diagnosis of eumycetoma); presence of white to yellow grains may indicate fungal or bacterial infection (eg, eumycetoma or actinomycetoma).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In the absence of sinus tracts or macroscopic grains, further diagnostic evaluation must be pursued, for mycetoma as well as other conditions. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definitive diagnosis
         </strong>
         − The evaluation usually consists of ultrasonography (demonstrating grains and/or cavities), followed by fine needle aspiration (FNA) to obtain material for histopathologic evaluation [
         <a href="#rid66">
          66,67
         </a>
         ]. FNA is preferred over extrusion of sinus material because sinus material is more likely to be nonviable and/or contaminated.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A definitive diagnosis of eumycetoma may be established by histopathologic evaluation demonstrating hyphae (facilitating discrimination between fungal and bacterial etiologies). Culture is required for species identification. Molecular tools are promising but costly and not universally available.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H892922939">
         <span class="h2">
          Diagnostic tools
         </span>
        </p>
        <p class="headingAnchor" id="H543095701">
         <span class="h3">
          Radiographic imaging
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Choice of modality
         </strong>
         − Useful radiographic tools for evaluation of suspected eumycetoma include ultrasonography, conventional radiography, computed tomography (CT), and magnetic resonance imaging (MRI) [
         <a href="#rid68">
          68
         </a>
         ]. The choice of initial modality should be guided by available resources. Ultrasonography is a reasonable initial modality; further imaging may be pursued depending on individual patient circumstances and available resources.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Ultrasonography
         </strong>
         − Ultrasound is a useful tool to distinguish mycetoma from other subcutaneous masses; the presence of grains may be demonstrated by sharp hyper-reflective echoes [
         <a href="#rid69">
          69
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Conventional radiography
         </strong>
         − Radiographic imaging is useful for evaluating the extent of soft tissue and bone involvement [
         <a href="#rid70">
          70
         </a>
         ]. Radiographic findings include soft tissue swelling, osteoporosis, and osteolytic lesions  (
         <a class="graphic graphic_diagnosticimage graphicRef69857" href="/z/d/graphic/69857.html" rel="external">
          image 1
         </a>
         ) [
         <a href="#rid71">
          71-73
         </a>
         ]. It is not possible to establish presence of grains with conventional radiography.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Computed tomography
         </strong>
         − CT is more sensitive than conventional radiography for assessing early bone involvement and osteoarticular damage. It is not possible to establish presence of grains with CT.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Magnetic resonance imaging
         </strong>
         − MRI is useful for assessing the scope of soft tissue involvement early in the course of disease, prior to development of sinus tracts and discharge [
         <a href="#rid68">
          68,74
         </a>
         ]. Presence of the "dot-in-circle sign" on MRI (multiple small, round to oval-shaped hyperintense lesions surrounded by a rim [circle] with a tiny central focus [dot]) correlates with inflammatory granulomata-containing grains, surrounded by fibrous matrix [
         <a href="#rid68">
          68,75
         </a>
         ]. This finding may be seen in eumycetoma or actinomycetoma.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Findings of bone involvement
         </strong>
         − Bone involvement usually occurs later in the course of disease. Bone cavity size depends on the grain size, which depends on the etiologic agent. In eumycetoma, cavitary bone lesions tend to be few in number and ≥1 cm in diameter, with well-defined margins. In contrast, cavitary bone lesions due to bacterial pathogens tend to be smaller and more numerous [
         <a href="#rid41">
          41,76
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2350746990">
         <span class="h3">
          Laboratory evaluation
         </span>
        </p>
        <p class="headingAnchor" id="H127131568">
         <span class="h4">
          Histopathology
         </span>
         <span class="headingEndMark">
          —
         </span>
         The histopathologic evaluation should include hematoxylin and eosin as well as periodic acid-Schiff or Gomori methenamine silver staining. Histopathologic findings of eumycetoma consist of a chronic granulomatous reaction with purulent center.
        </p>
        <p>
         Grains of different morphologies may be observed; characteristics of grains inside the tissue may vary depending on the specific etiology  (
         <a class="graphic graphic_picture graphicRef78858" href="/z/d/graphic/78858.html" rel="external">
          picture 6
         </a>
         and
         <a class="graphic graphic_picture graphicRef50368" href="/z/d/graphic/50368.html" rel="external">
          picture 7
         </a>
         ). Hyphae (broad, septate, and branching hyphae with large swollen cells at the edge) may be observed within grains or in the absence of grains; hyphae may be hyaline or pigmented. Grain cement (composed of melanoproteins) may or may not be seen; if present, it may be compact or loose [
         <a href="#rid77">
          77
         </a>
         ]. (See
         <a class="local">
          'Microbiology'
         </a>
         above.)
        </p>
        <p>
         Certain characteristics may be helpful for presumptive species identification:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          M. mycetomatis
         </em>
         grains are 0.5 to 3 mm, appear rounded, oval, or trilobed, and consist of intertwining hyphae embedded in interstitial brownish cement. Grains may be of filamentous and/or vesicular types; either or both may be observed in the same lesion [
         <a href="#rid78">
          78
         </a>
         ]. A filamentous grain may include brown septate and branched hyphae in the periphery; a vesicular grain may contain unusually large cells that look like vesicles. These findings may be used for presumptive identification but may not be used for definitive diagnosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          S. apiospermum
         </em>
         species complex grains are eosinophilic with a clear central area, abundant swollen cells, and without cement. Fluorescent antibody reagents have been developed to detect
         <em>
          S. apiospermum
         </em>
         species complex in tissues, providing a rapid, reliable method for diagnosis [
         <a href="#rid79">
          79
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2959288569">
         <span class="h4">
          Grain identification and fungal culture
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Obtaining material
         </strong>
         − FNA is preferred over extrusion of sinus material. Collected material should be sent for grain evaluation (macroscopic and microscopic), fungal culture, and histopathologic evaluation [
         <a href="#rid66">
          66
         </a>
         ]. (See
         <a class="local">
          'General approach'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Grain evaluation
         </strong>
         − Grains contain colonies of the causative organism  (
         <a class="graphic graphic_table graphicRef58060" href="/z/d/graphic/58060.html" rel="external">
          table 1
         </a>
         ); they may be observed macroscopically and/or microscopically. In direct microscopic examination, grains are mounted on a slide and crushed under a cover glass. Grains should be examined with 20% potassium hydroxide solution to identify fungal structures (broad, septate, and branching hyphae with large swollen cells at the edge)  (
         <a class="graphic graphic_picture graphicRef67692" href="/z/d/graphic/67692.html" rel="external">
          picture 8
         </a>
         ). Gram staining may be useful to demonstrate the presence of bacteria causing actinomycetoma. In some cases, grains are visible only by histopathologic examination. (See
         <a class="local">
          'Histopathology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Black grains reflect fungal infection, establishing a diagnosis of eumycetoma;
         <em>
          M. mycetomatis
         </em>
         is the most common cause of black-grain eumycetoma. White to yellow grains may reflect fungal or bacterial infection;
         <em>
          S. apiospermum
         </em>
         species complex are the most common causes of white-grain eumycetoma. (See
         <a class="local">
          'Microbiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Culture
         </strong>
         − Grains and tissue from deep aspiration or biopsy must be cultured for definitive species identification. The causative agents of eumycetoma grow as molds with septate hyphae. Culture specimens should be washed with sterile
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         solution prior to inoculation onto Sabouraud dextrose agar medium (with and without
         <a class="drug drug_general" data-topicid="9241" href="/z/d/drug information/9241.html" rel="external">
          chloramphenicol
         </a>
         and cycloheximide).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         To increase yield, tissue samples should be plated without grinding. Two sets of media should be inoculated; one plate should be incubated at 25°C (room temperature) and the other plate should be incubated at 37°C. The plates should be incubated for six to eight weeks, since some causative agents grow relatively slowly. Following successful isolation in culture, standard mycologic or molecular techniques may be used for identification.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h4">
          Molecular testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Molecular techniques are reliable for identification of causative agents of eumycetoma; tools include 16S rRNA gene sequencing studies and species-specific polymerase chain reaction for the most prevalent organisms. Molecular tools are especially useful for circumstances in which macroscopic and microscopic features are not sufficient for precise identification, due to absence of distinctive structures. Molecular test results are available in a few hours (whereas culture requires at least a couple weeks) [
         <a href="#rid80">
          80
         </a>
         ]. These tests are costly and not universally available but may be performed in specialized laboratories.
        </p>
        <p>
         A novel molecular technique consists of rolling circle amplification (RCA), which involves isothermal amplification of circular DNA molecules. This is a rapid and specific tool for diagnosis of black-grain eumycetoma-causative agents (
         <em>
          M. fahalii
         </em>
         ,
         <em>
          M. mycetomatis
         </em>
         ,
         <em>
          M. pseudomycetomatis
         </em>
         ,
         <em>
          M. tropicana
         </em>
         ,
         <em>
          T. grisea
         </em>
         ,
         <em>
          F. senegalensis
         </em>
         ,
         <em>
          Falciformispora tompkinsii
         </em>
         , and
         <em>
          Medicopsis romeroi
         </em>
         ); it has specificity of 100 percent with no cross reactivity [
         <a href="#rid81">
          81
         </a>
         ]. RCA also has been used for identification of a white-grain eumycetoma agent,
         <em>
          Scedosporium boydii
         </em>
         [
         <a href="#rid82">
          82
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H5841269">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Conditions that may present with a triad of tumor (painless firm subcutaneous mass), sinus tracts, and discharge-containing grains (macroscopic or microscopic) include mycetoma (eumycetoma or actinomycetoma) and botryomycosis. Eumycetoma is caused by fungal infection, actinomycetoma is caused by bacterial infection (most commonly nocardia), and botryomycosis is caused by bacterial infection (most commonly
         <em>
          S. aureus
         </em>
         ). Actinomycetoma is more aggressive and destructive than eumycetoma, with earlier bone invasion. The infections may be distinguished based on Gram stain and culture. (See
         <a class="medical medical_review" href="/z/d/html/7649.html" rel="external">
          "Botryomycosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5515.html" rel="external">
          "Nocardia infections: Epidemiology, clinical manifestations, and diagnosis", section on 'Skin'
         </a>
         .)
        </p>
        <p>
         Other considerations in the differential diagnosis of eumycetoma depend on the stage of the lesion.
        </p>
        <p>
         The differential diagnosis of early lesions includes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Foreign body granuloma – A foreign body granuloma is a response of biologic material to foreign material in the tissue. The diagnosis may be established radiographically or via biopsy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Soft tissue tumor – Soft tissue swelling may reflect a benign soft tissue tumor (such as a lipoma) or a malignant tumor (such as sarcoma, metastatic carcinoma, melanoma, or lymphoma). The diagnosis is established via biopsy. (See
         <a class="medical medical_review" href="/z/d/html/14259.html" rel="external">
          "Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cystic lesion – A cyst is a closed pocket of tissue that may be filled with fluid, pus, or other material. Epidermoid cysts are the most common cutaneous cysts; the diagnosis is usually based on the clinical appearance of a discrete nodule, often with a central punctum that is freely movable on palpation. (See
         <a class="medical medical_review" href="/z/d/html/5573.html" rel="external">
          "Overview of benign lesions of the skin", section on 'Cysts'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Folliculitis – Folliculitis is a superficial infection of the hair follicles with purulent material in the epidermis. The diagnosis of folliculitis is based upon clinical manifestations. (See
         <a class="medical medical_review" href="/z/d/html/103297.html" rel="external">
          "Infectious folliculitis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         The differential diagnosis in the absence of sinus tracts or grains includes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sporotrichosis – Sporotrichosis is a subacute to chronic infection caused by species from the
         <em>
          Sporothrix schenckii
         </em>
         complex. Infection usually involves cutaneous and subcutaneous tissues but can occasionally occur in other sites. The diagnosis is established via culture. (See
         <a class="medical medical_review" href="/z/d/html/2457.html" rel="external">
          "Clinical features and diagnosis of sporotrichosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chromoblastomycosis – Chromoblastomycosis is a subcutaneous fungal infection caused by one of several dematiaceous (pigmented) fungi. Examination of skin scrapings with potassium hydroxide or skin biopsy demonstrates characteristic pigmented Medlar bodies, which are thick-walled structures 4 to 12 micrometers in diameter that are globe shaped and copper colored. Fungal culture allows species differentiation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cutaneous leishmaniasis – Cutaneous leishmaniasis is a protozoal infection that produces skin ulcers. The diagnosis requires demonstration of the parasite in a clinical specimen (usually skin) by histology, culture, or molecular analysis via polymerase chain reaction. (See
         <a class="medical medical_review" href="/z/d/html/5689.html" rel="external">
          "Cutaneous leishmaniasis: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mycobacterial infection – Cutaneous tuberculosis, tuberculous lymphadenitis, and atypical mycobacterial infection may present with skin lesions and draining sinus tracts. (See
         <a class="medical medical_review" href="/z/d/html/15866.html" rel="external">
          "Cutaneous manifestations of tuberculosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5342.html" rel="external">
          "Overview of nontuberculous mycobacterial infections"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5349.html" rel="external">
          "Buruli ulcer (Mycobacterium ulcerans infection)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Elephantiasis – Elephantiasis refers to severe lymphedema that occurs in the setting of filariasis, which is caused by nematodes (roundworms) that inhabit the lymphatics and subcutaneous tissues. The diagnosis is established via antigen testing and/or blood smear examination. (See
         <a class="medical medical_review" href="/z/d/html/5675.html" rel="external">
          "Lymphatic filariasis: Epidemiology, clinical manifestations, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5680.html" rel="external">
          "Lymphatic filariasis: Treatment and prevention"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Podoconiosis – Podoconiosis is an inflammatory reaction to mineral particles in certain soils that can result in lymphedema and elephantiasis. Podoconiosis occurs in the tropics at altitudes higher than those at which mosquitoes can transmit filarial infection (a maximum of about 1500 meters, or 4920 feet).
        </p>
        <p>
        </p>
        <p>
         Bone involvement should prompt consideration of:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bacterial osteomyelitis – The diagnosis of osteomyelitis is established via isolation of bacteria from a bone biopsy sample together with histologic findings of inflammation and osteonecrosis. (See
         <a class="medical medical_review" href="/z/d/html/7668.html" rel="external">
          "Nonvertebral osteomyelitis in adults: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Skeletal tuberculosis – The diagnosis of musculoskeletal tuberculosis is established by microscopy and culture of infected material. (See
         <a class="medical medical_review" href="/z/d/html/7658.html" rel="external">
          "Bone and joint tuberculosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Malignant bone tumor – Bone tumors include osteosarcoma, chondrosarcoma, Ewing sarcoma, and other tumors. The diagnosis is established via histopathology. (See
         <a class="medical medical_review" href="/z/d/html/7741.html" rel="external">
          "Bone tumors: Diagnosis and biopsy techniques"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Yaws – Yaws is a nonvenereal treponematosis endemic in rural areas among communities living in overcrowded conditions with poor hygiene. It usually occurs in children and affects skin and bones; it is transmitted by direct skin-to-skin, nonsexual contact with infectious lesions. The diagnosis is established via serology. (See
         <a class="medical medical_review" href="/z/d/html/87120.html" rel="external">
          "Yaws, bejel, and pinta"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h1">
          TREATMENT
         </span>
        </p>
        <p class="headingAnchor" id="H2240517526">
         <span class="h2">
          General approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment of eumycetoma requires prolonged antifungal therapy. The optimal role for surgery is uncertain; if pursued, surgery should be performed after at least six months of antifungal therapy. There are no randomized trials to guide treatment; the approach is based on small case reports with limited follow-up.
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Antifungal therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment consists of azole antifungal therapy, based on reported in-vitro susceptibility data. Agents with inadequate activity include amphotericin, echinocandins,
         <a class="drug drug_general" data-topicid="9677" href="/z/d/drug information/9677.html" rel="external">
          terbinafine
         </a>
         , and 5-flucytosine.
        </p>
        <p>
         The choice of antifungal therapy is guided by grain type. Identification of the causative agent is important to guide the choice of treatment, given variability in antifungal susceptibility among species [
         <a href="#rid80">
          80
         </a>
         ]. However, the choice and duration of antifungal therapy must be tailored to individual patient circumstances, as in vitro susceptibility testing does not always predict the clinical response to therapy.
        </p>
        <p>
         If differentiation between eumycetoma and actinomycetoma is not possible, we administer initial empiric treatment for actinomycetoma; this condition generally responds more rapidly to treatment. In the absence of clinical improvement after eight weeks of empiric treatment for actinomycetoma, we switch to treatment for eumycetoma. (See
         <a class="medical medical_review" href="/z/d/html/5513.html" rel="external">
          "Treatment of nocardiosis", section on 'Mycetoma'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3286452573">
         <span class="h3">
          Black grain
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Our approach
         </strong>
         − For treatment of the most frequently observed black-grain eumycetomas (
         <em>
          M. mycetomatis
         </em>
         ,
         <em>
          T. grisea,
         </em>
         and
         <em>
          F. senegalensis
         </em>
         ), we favor
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         (200 mg orally twice daily); the duration should be at least 12 months and depends in part on decisions regarding surgical intervention. (See
         <a class="local">
          'Surgery'
         </a>
         below and
         <a class="local">
          'Duration of treatment and follow-up'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Given variable serum levels of
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         , serum drug-level monitoring should be performed (if feasible) after steady state has been reached (about two weeks), with goal serum level &gt;1 mcg/mL.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Alternative agents
         </strong>
         − For patients with intolerance or whose disease is refractory to
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         , acceptable alternatives include
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         or
         <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">
          posaconazole
         </a>
         ; disease is considered refractory to itraconazole if there is clinical progression despite at least three months of treatment [
         <a href="#rid83">
          83
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          Voriconazole
         </a>
         and
         <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">
          posaconazole
         </a>
         have been assessed in a small number of patients with promising results; as with
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         , a prolonged duration of treatment is required [
         <a href="#rid83">
          83-88
         </a>
         ]. Dosing is as outlined below. (See
         <a class="local">
          'White to yellow grain'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Clinical data on other agents such as
         <a class="drug drug_general" data-topicid="100324" href="/z/d/drug information/100324.html" rel="external">
          isavuconazole
         </a>
         are limited but could be promising given favorable pharmacokinetic characteristics [
         <a href="#rid89">
          89,90
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          In vitro susceptibility
         </strong>
         − In vitro susceptibility of
         <em>
          M. mycetomatis
         </em>
         is favorable for
         <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">
          ketoconazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">
          posaconazole
         </a>
         , and
         <a class="drug drug_general" data-topicid="100324" href="/z/d/drug information/100324.html" rel="external">
          isavuconazole
         </a>
         ;
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          fluconazole
         </a>
         should not be used due to intrinsic resistance [
         <a href="#rid89">
          89,91-93
         </a>
         ]. Similar susceptibility results have been observed with other causative agents of black-grain eumycetoma [
         <a href="#rid90">
          90
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">
          Ketoconazole
         </a>
         was the mainstay of therapy for many years; however, its use has been restricted by the US Food and Drug Administration in 2013 because of a high rate of adverse effects including hepatotoxicity, QT prolongation, and drug interactions.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Supporting evidence
         </strong>
         – Use of
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         is supported by a study including 13 patients with
         <em>
          M. mycetomatis
         </em>
         treated with itraconazole (400 mg daily for three months, followed by 200 mg daily for nine months). The initial clinical response was favorable (as demonstrated by improvement of overlying skin appearance, reduced swelling, diminished discharge, and progressive healing of sinus tracts) but slowed when the dose was reduced [
         <a href="#rid94">
          94
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1742288258">
         <span class="h3">
          White to yellow grain
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Our approach
         </strong>
         – For treatment of eumycetoma due to
         <em>
          S. apiospermum
         </em>
         species complex, we favor
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         (loading dose 400 mg orally every 12 hours for the first 24 hours, followed by 200 mg twice daily; the dose may be increased to 300 mg twice daily if needed). The duration consists of at least 12 months, and depends in part on decisions regarding surgical intervention (see
         <a class="local">
          'Surgery'
         </a>
         below and
         <a class="local">
          'Duration of treatment and follow-up'
         </a>
         below). Given variable serum levels of voriconazole, serum drug level monitoring should be performed (if feasible) after steady state has been reached (about five to seven days) with goal serum level 1 to 5 mcg/mL [
         <a href="#rid95">
          95
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Alternative agents
         </strong>
         – For patients with intolerance or whose infection is refractory to
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         , acceptable alternatives include
         <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">
          posaconazole
         </a>
         extended-release tablets (300 mg twice daily for the first day, then 300 mg daily) or posaconazole oral suspension (200 mg four times daily or 400 mg twice daily) [
         <a href="#rid83">
          83,96-98
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Supporting evidence
         </strong>
         – The above approach is supported by studies describing use of
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         for treatment of invasive infection, including severe and disseminated disease involving bone and central nervous system, due to
         <em>
          S. apiospermum
         </em>
         species complex with favorable results (as demonstrated by improvement of overlying skin appearance, reduced swelling, diminished discharge, and progressive healing of sinus tracts) [
         <a href="#rid84">
          84,99-103
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Clinical data on treatment
         <em>
          of Scedosporium
         </em>
         infection are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/2429.html" rel="external">
          "Treatment of Scedosporium and Lomentospora infections"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          Surgery
         </span>
         <span class="headingEndMark">
          —
         </span>
         The optimal role of surgery for management of eumycetoma is uncertain and the indications and techniques for management are not well standardized [
         <a href="#rid104">
          104
         </a>
         ]. If surgery is performed, it should always be in conjunction with antifungal treatment.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Small, well-demarcated lesions
         </strong>
         − For patients with small, well-demarcated lesions, in the absence of bone involvement, we favor early surgery in regions with appropriate expertise; in such cases, a wide margin of healthy tissue should be excised [
         <a href="#rid105">
          105
         </a>
         ]. If surgical excision is pursued, at least six months of antifungal therapy should be administered prior to debridement, to enhance encapsulation and reduce the burden of infection, facilitating local excision [
         <a href="#rid94">
          94,106
         </a>
         ]. In addition, antifungal drugs should be administered following surgery for at least 12 months, to reduce the likelihood of recurrence [
         <a href="#rid106">
          106,107
         </a>
         ]. Following excision, primary closure or reconstruction with flaps or grafts is performed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The above approach is supported by a study including 13 patients with
         <em>
          M. mycetomatis
         </em>
         treated with
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         for 12 months prior to debridement. In all patients the lesions were well localized and easily resected [
         <a href="#rid94">
          94
         </a>
         ]. No postoperative antifungal treatment was administered; after a follow-up period ranging from 18 to 36 months, one patient presented with recurrence.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bone involvement
         </strong>
         − In the setting of bone involvement, definitive management may require amputation [
         <a href="#rid105">
          105
         </a>
         ]. Amputation also may be pursued in cases of severe, progressive disability [
         <a href="#rid105">
          105
         </a>
         ]; in such cases, the goal of amputation should be to prevent further deterioration in quality of life.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h2">
          Duration of treatment and follow-up
         </span>
         <span class="headingEndMark">
          —
         </span>
         The optimal duration of antimicrobial therapy for treatment of eumycetoma is uncertain and depends on individual circumstances. In general, at least 12 months of therapy is appropriate; treatment may be required for two years or more. Bone involvement indicates a poor prognosis and requires a longer course of therapy. Hepatic enzyme monitoring should be performed monthly during azole therapy.
        </p>
        <p>
         Treatment should be continued for at least three months after a clinical and radiographic cure is achieved. Clinical signs of improvement include reduction in swelling, decreasing purulent discharge, closing of sinus tracts, reduction in pain, and improvement of mobility. Radiographic signs of improvement include resolution of soft tissue involvement and improvement in bone lesions; ultrasonographic signs of improvement include disappearance of grains and cavities. Patients should be followed for at least two years after discontinuation of antimicrobial therapy before declaring a cure [
         <a href="#rid23">
          23
         </a>
         ]. We do not perform biopsy to assess for cure.
        </p>
        <p class="headingAnchor" id="H444432630">
         <span class="h1">
          OUTCOMES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Relapse is common and is attributable to several factors. In one study that included 1013 patients in Sudan who had eumycetoma due to
         <em>
          M. mycetomatis
         </em>
         and who underwent surgical excision
         <em>
          ,
         </em>
         relapse occurred in 27 percent of cases. Risk factors for relapse included disease duration ≥10 years, extrapedal involvement, previous surgical excision, and family history of mycetoma [
         <a href="#rid108">
          108
         </a>
         ]. In a subsequent study including more than 500 patients in Sudan with eumycetoma who underwent excision, the recurrence rate at 18-month follow-up was 5.5 percent; risk factors included bone involvement, recurrent disease, and lesion size ≥5 cm [
         <a href="#rid109">
          109
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h1">
          PREVENTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Use of protective equipment including shoes and gloves should be promoted in the setting of contact with soil whenever possible. In addition, health care professionals working in endemic areas must be educated to recognize and treat eumycetoma promptly before progression to advanced disease.
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition
         </strong>
         − Mycetoma is a chronic skin and soft tissue infection resulting in a mass, sinus formation, and discharge-containing grains. Surrounding tissues can be involved by contiguous spread. Mycetoma can be caused by fungi (eumycetoma) or bacteria (actinomycetoma, most commonly actinomyces, streptomyces, or
         <em>
          Nocardia
         </em>
         species). (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology
         </strong>
         − Most cases of eumycetoma occur in resource-limited countries in tropical and subtropical regions, although cases have been reported worldwide. Eumycetoma most frequently involves the feet, followed by legs and hands, where exposure to contaminated soil occurs most commonly. (See
         <a class="local">
          'Epidemiology'
         </a>
         above and
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathogenesis
         </strong>
         − Eumycetoma begins with traumatic inoculation of the organism into cutaneous and/or subcutaneous tissues. Trauma may be minor (due to thorns, splinters, or other objects), and patients may not recall a specific injury. Grains (colonies of infecting organisms) are formed in infected tissues. The grains are partially broken down via a neutrophil-mediated inflammatory reaction; their remains perpetuate an inflammatory response. (See
         <a class="local">
          'Pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Microbiology
         </strong>
         − Organisms capable of causing eumycetoma are distributed worldwide and include at least 44 hyaline and pigmented species of molds  (
         <a class="graphic graphic_table graphicRef58060" href="/z/d/graphic/58060.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_figure graphicRef61250" href="/z/d/graphic/61250.html" rel="external">
          figure 1
         </a>
         ). (See
         <a class="local">
          'Microbiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – A clinical diagnosis of mycetoma may be established in patients with the characteristic triad of tumor, sinus tracts, and discharge-containing grains. The evaluation usually consists of ultrasonography (demonstrating grains and/or cavities) followed by fine needle aspiration. A definitive diagnosis of eumycetoma may be established by histopathologic evaluation demonstrating hyphae; culture is required for species identification. (See
         <a class="local">
          'General approach'
         </a>
         above and
         <a class="local">
          'Laboratory evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Grain identification
         </strong>
         − Grains may be observed macroscopically and/or microscopically; in some cases, they are visible only by histopathologic examination. Black grains reflect fungal infection, establishing a diagnosis of eumycetoma; white to yellow grains may reflect fungal or bacterial infection. (See
         <a class="local">
          'Grain identification and fungal culture'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
         − Treatment of eumycetoma requires prolonged antifungal therapy and surgery in some cases.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Antifungal therapy
         </strong>
         − The choice of antifungal therapy is guided by grain type. Identification of the causative agent is important, given variability in antifungal susceptibility between species. However, the choice and duration of antifungal therapy must be tailored to individual patient circumstances, as in vitro susceptibility testing does not always predict the clinical response to therapy. (See
         <a class="local">
          'Antifungal therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Selection
         </strong>
         − For treatment of black-grain eumycetomas caused
         <em>
          by Madurella mycetomatis, Trematosphaeria grisea
         </em>
         ,
         <em>
          or Falciformispora senegalensis,
         </em>
         we suggest
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         rather than other azoles (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         For treatment of white to yellow grain eumycetomas caused by
         <em>
          Scedosporium apiospermum
         </em>
         species complex, we suggest
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         rather than other azoles (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Antifungal therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Duration
         </strong>
         − The duration of antifungal treatment is at least 12 months, tailored to individual patient circumstances.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         Treatment should be continued for at least three months after a clinical and radiographic cure is achieved. (See
         <a class="local">
          'Duration of treatment and follow-up'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Surgery
         </strong>
         − For patients with small, well-demarcated lesions in the absence of bone involvement, we suggest early surgical excision in regions with appropriate expertise (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). In such cases, we administer antifungal therapy for at least six months prior to debridement and at least 12 months afterwards.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         In the setting of bone involvement, definitive management may require amputation. (See
         <a class="local">
          'Surgery'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Zijlstra EE, van de Sande WW, Welsh O, et al. Mycetoma: a unique neglected tropical disease. Lancet Infect Dis 2016; 16:100.
          </a>
         </li>
         <li class="breakAll">
          World Health Organization. Addressing the burden of mycetoma, 28 May 2016. http://www.who.int/neglected_diseases/mediacentre/WHA_69.21_Eng.pdf?ua=1&amp;ua=1 (Accessed on August 31, 2017).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fahal A, Mahgoub el S, El Hassan AM, Abdel-Rahman ME. Mycetoma in the Sudan: an update from the Mycetoma Research Centre, University of Khartoum, Sudan. PLoS Negl Trop Dis 2015; 9:e0003679.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Develoux M, Audoin J, Treguer J, et al. Mycetoma in the Republic of Niger: clinical features and epidemiology. Am J Trop Med Hyg 1988; 38:386.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ndiaye D, Ndiaye M, Sène PD, et al. [Mycetomas diagnosed in Senegal from 2008 to 2010]. J Mycol Med 2011; 21:173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Philippon M, Larroque D, Ravisse P. Mycétomes en Mauritanie, espèces rencontrées, caractères épidémiologiques et répartition dans le pays. A propos de 122 cas. Bull Soc Pathol Exot 1992; 85:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           ABBOTT P. Mycetoma in the Sudan. Trans R Soc Trop Med Hyg 1956; 50:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yu AM, Zhao S, Nie LY. Mycetomas in northern Yemen: identification of causative organisms and epidemiologic considerations. Am J Trop Med Hyg 1993; 48:812.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee MW, Kim JC, Choi JS, et al. Mycetoma caused by Acremonium falciforme: successful treatment with itraconazole. J Am Acad Dermatol 1995; 32:897.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fahal AH, el Toum EA, el Hassan AM, et al. The host tissue reaction to Madurella mycetomatis: new classification. J Med Vet Mycol 1995; 33:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van de Sande WW, de Kat J, Coppens J, et al. Melanin biosynthesis in Madurella mycetomatis and its effect on susceptibility to itraconazole and ketoconazole. Microbes Infect 2007; 9:1114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verwer PE, Notenboom CC, Eadie K, et al. A Polymorphism in the Chitotriosidase Gene Associated with Risk of Mycetoma Due to Madurella mycetomatis Mycetoma--A Retrospective Study. PLoS Negl Trop Dis 2015; 9:e0004061.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van de Sande WW, Fahal A, Verbrugh H, van Belkum A. Polymorphisms in genes involved in innate immunity predispose toward mycetoma susceptibility. J Immunol 2007; 179:3065.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neumeister B, Zollner TM, Krieger D, et al. Mycetoma due to Exophiala jeanselmei and Mycobacterium chelonae in a 73-year-old man with idiopathic CD4+ T lymphocytopenia. Mycoses 1995; 38:271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Satta R, Sanna S, Cottoni F. Madurella infection in an immunocompromised host. Int J Dermatol 2000; 39:939.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Geyer AS, Fox LP, Husain S, et al. Acremonium mycetoma in a heart transplant recipient. J Am Acad Dermatol 2006; 55:1095.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meis JF, Schouten RA, Verweij PE, et al. Atypical presentation of Madurella mycetomatis mycetoma in a renal transplant patient. Transpl Infect Dis 2000; 2:96.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Riordan E, Denton J, Taylor PM, et al. Madura foot in the U.K.: fungal osteomyelitis after renal transplantation. Transplantation 2002; 73:151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Etta LL, Peterson LR, Gerding DN. Acremonium falciforme (Cephalosporium falciforme) mycetoma in a renal transplant patient. Arch Dermatol 1983; 119:707.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hay RJ, Mahgoub ES, Leon G, et al. Mycetoma. J Med Vet Mycol 1992; 30 Suppl 1:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahgoub ES, Gumaa SA, El Hassan AM. Immunological status of mycetoma patients. Bull Soc Pathol Exot Filiales 1977; 70:48.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nasr A, Abushouk A, Hamza A, et al. Th-1, Th-2 Cytokines Profile among Madurella mycetomatis Eumycetoma Patients. PLoS Negl Trop Dis 2016; 10:e0004862.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bendl BJ, Mackey D, Al-Saati F, et al. Mycetoma in Saudi Arabia. J Trop Med Hyg 1987; 90:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hemashettar BM, Siddaramappa B, Munjunathaswamy BS, et al. Phaeoacremonium krajdenii, a cause of white grain eumycetoma. J Clin Microbiol 2006; 44:4619.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aguilar-Donis A, Torres-Guerrero E, Arenas-Guzmán R, et al. Mycetoma caused by Phaeoacremonium parasiticum--a case confirmed with B-tubulin sequence analysis. Mycoses 2011; 54:e615.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Hoog GS, van Diepeningen AD, Mahgoub el-S, van de Sande WW. New species of Madurella, causative agents of black-grain mycetoma. J Clin Microbiol 2012; 50:988.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hashemi SJ, Nasrollahi A, Guerami M, et al. Mycetoma in Iran: study of 62 cases. Asian J Epidemiol 2008; 1:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iriart X, Binois R, Fior A, et al. Eumycetoma caused by Diaporthe phaseolorum (Phomopsis phaseoli): a case report and a mini-review of Diaporthe/Phomopsis spp invasive infections in humans. Clin Microbiol Infect 2011; 17:1492.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mhmoud NA, Ahmed SA, Fahal AH, et al. Pleurostomophora ochracea, a novel agent of human eumycetoma with yellow grains. J Clin Microbiol 2012; 50:2987.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Motswaledi HM, Mathekga K, Sein PP, Nemutavhanani DL. Paecilomyces lilacinus eumycetoma. Int J Dermatol 2009; 48:858.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Campos-Macías P, Arenas-Guzmán R, Hernández-Hernández F. Fusarium subglutinans: A new eumycetoma agent. Med Mycol Case Rep 2013; 2:128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borman AM, Desnos-Ollivier M, Campbell CK, et al. Novel Taxa Associated with Human Fungal Black-Grain Mycetomas: Emarellia grisea gen. nov., sp. nov., and Emarellia paragrisea sp. nov. J Clin Microbiol 2016; 54:1738.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahmed SA, van de Sande WW, Stevens DA, et al. Revision of agents of black-grain eumycetoma in the order Pleosporales. Persoonia 2014; 33:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Al-Hatmi AM, Bonifaz A, Tirado-Sánchez A, et al. Fusarium species causing eumycetoma: Report of two cases and comprehensive review of the literature. Mycoses 2017; 60:204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bustamante B, Ahmed SA, De Hoog GS, et al. Phaeoacremonium sphinctrophorum as a Novel Agent of Eumycetoma. JAMA Dermatol 2016; 152:1063.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahmed SA, González GM, Tirado-Sánchez A, et al. Nigrograna mackinnonii, Not Trematosphaeria grisea (syn., Madurella grisea), Is the Main Agent of Black Grain Eumycetoma in Latin America. J Clin Microbiol 2018; 56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van de Sande WW. Global burden of human mycetoma: a systematic review and meta-analysis. PLoS Negl Trop Dis 2013; 7:e2550.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hay RJ, Collins MJ. An ultrastructural study of pale eumycetoma grains. Sabouraudia 1983; 21:261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahmed EA, Nour BYM, Abakar AD, et al. The genus Madurella: Molecular identification and epidemiology in Sudan. PLoS Negl Trop Dis 2020; 14:e0008420.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yan J, Deng J, Zhou CJ, et al. Phenotypic and molecular characterization of Madurella pseudomycetomatis sp. nov., a novel opportunistic fungus possibly causing black-grain mycetoma. J Clin Microbiol 2010; 48:251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boiron P, Locci R, Goodfellow M, et al. Nocardia, nocardiosis and mycetoma. Med Mycol 1998; 36 Suppl 1:26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           MARIAT F. [On the geographic distribution and incidence of mycetoma agents]. Bull Soc Pathol Exot Filiales 1963; 56:35.
          </a>
         </li>
         <li class="breakAll">
          Mahgoub ES. Mycetoma. In: Tropical Mycoses, Mahgoub ES (Ed), Jansen Research Council, 1989. p.57.
         </li>
         <li class="breakAll">
          Rippon JW. Medical mycology: the pathogenic fungi and the pathogenic actinomycetes, 2nd ed, WB Saunders Co, Philadelphia 1982. p.596.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nyuykonge B, Klaassen CHW, Zandijk WHA, et al. Diagnostic implications of mycetoma derived from Madurella pseudomycetomatis isolates from Mexico. J Eur Acad Dermatol Venereol 2020; 34:1828.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gezuele E, Mackinnon JE, Conti-Díaz IA. The frequent isolation of Phialophora verrucosa and Phialophora pedrosoi from natural sources. Sabouraudia 1972; 10:266.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahmed A, Adelmann D, Fahal A, et al. Environmental occurrence of Madurella mycetomatis, the major agent of human eumycetoma in Sudan. J Clin Microbiol 2002; 40:1031.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Segretain G, Mariat F. [Research on the presence of agents of mycetoma in the soil and thorny plants of Senegal and Mauritania]. Bull Soc Pathol Exot Filiales 1968; 61:194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Segretain G. [Epidemiology of mycetomas]. Ann Soc Belg Med Trop 1972; 52:277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maiti PK, Ray A, Bandyopadhyay S. Epidemiological aspects of mycetoma from a retrospective study of 264 cases in West Bengal. Trop Med Int Health 2002; 7:788.
          </a>
         </li>
         <li class="breakAll">
          Bustamante B, Campos PE. Eumycetoma. In: Atlas of fungal infections, 2nd, Kauffman CA (Ed), Current Medicine LLC, 2007. p.203.
         </li>
         <li>
          <a class="nounderline abstract_t">
           López Martínez R, Méndez Tovar LJ, Lavalle P, et al. [Epidemiology of mycetoma in Mexico: study of 2105 cases]. Gac Med Mex 1992; 128:477.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soni N, Gupta A, Shekhawat NS. Mycetoma - an unusual site. Surgery 2000; 127:709.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ly F, Develoux M, Deme A, et al. [Tumoral mycetoma of the buttock]. Ann Dermatol Venereol 2000; 127:67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gumaa SA, Satir AA, Shehata AH, Mahgoub ES. Tumor of the mandible caused by Madurella mycetomil. Am J Trop Med Hyg 1975; 24:471.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arbab MA, el Hag IA, Abdul Gadir AF, Siddik H el-R . Intraspinal mycetoma: report of two cases. Am J Trop Med Hyg 1997; 56:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fahal AH, el Hassan AM, Abdelalla AO, Sheik HE. Cystic mycetoma: an unusual clinical presentation of Madurella mycetomatis infection. Trans R Soc Trop Med Hyg 1998; 92:66.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           el Hassan AM, Mahgoub ES. Lymph node involvement in mycetoma. Trans R Soc Trop Med Hyg 1972; 66:165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zaid DM, Bakheet OE, Ahmed ES, et al. Multiple extensive Madurella mycetomatis eumycetoma lesions: a case report and review of the literature. Trans R Soc Trop Med Hyg 2021; 115:411.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castro LG, Belda Júnior W, Salebian A, Cucé LC. Mycetoma: a retrospective study of 41 cases seen in São Paulo, Brazil, from 1978 to 1989. Mycoses 1993; 36:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saad ESA, Fahal AH. Broncho-pleuro-cutaneous fistula and pneumothorax: Rare challenging complications of chest wall eumycetoma. PLoS Negl Trop Dis 2017; 11:e0005737.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mohamed NA, Fahal AH. Mycetoma Pulmonary Secondaries from a Gluteal Eumycetoma: An Unusual Presentation. PLoS Negl Trop Dis 2016; 10:e0004945.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mohamed el SW, Seif El Din N, Fahal AH. Multiple Mycetoma Lung Secondaries from Knee Eumycetoma: An Unusual Complication. PLoS Negl Trop Dis 2016; 10:e0004735.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scolding PS, Abbas MA, Omer RF, Fahal AH. Madurella mycetomatis-Induced Massive Shoulder Joint Destruction: A Management Challenge. PLoS Negl Trop Dis 2016; 10:e0004849.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahmed AO, Abugroun ES. Unexpected high prevalence of secondary bacterial infection in patients with mycetoma. J Clin Microbiol 1998; 36:850.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gabhane SK, Gangane N, Anshu . Cytodiagnosis of eumycotic mycetoma: a case report. Acta Cytol 2008; 52:354.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siddig EE, Mhmoud NA, Bakhiet SM, et al. The Accuracy of Histopathological and Cytopathological Techniques in the Identification of the Mycetoma Causative Agents. PLoS Negl Trop Dis 2019; 13:e0007056.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bahar ME, Bakheet OELH, Fahal AH. Mycetoma imaging: the best practice. Trans R Soc Trop Med Hyg 2021; 115:387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fahal AH, Sheik HE, Homeida MM, et al. Ultrasonographic imaging of mycetoma. Br J Surg 1997; 84:1120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Czechowski J, Nork M, Haas D, et al. MR and other imaging methods in the investigation of mycetomas. Acta Radiol 2001; 42:24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Al-Ali AA, Kashgari TQ, Nathani PG, Moawad MK. Radiological manifestations of madura foot in the Eastern Province of Saudi Arabia. Ann Saudi Med 1997; 17:298.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abd Bagi ME, Fahal AH, Sheik HE, et al. Pathological fractures in mycetoma. Trans R Soc Trop Med Hyg 2003; 97:582.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tomimori-Yamashita J, Ogawa MM, Hirata SH, et al. Mycetoma caused by Fusarium solani with osteolytic lesions on the hand: case report. Mycopathologia 2002; 153:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           El Shamy ME, Fahal AH, Shakir MY, Homeida MM. New MRI grading system for the diagnosis and management of mycetoma. Trans R Soc Trop Med Hyg 2012; 106:738.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sarris I, Berendt AR, Athanasous N, et al. MRI of mycetoma of the foot: two cases demonstrating the dot-in-circle sign. Skeletal Radiol 2003; 32:179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McGinnis MR. Mycetoma. Dermatol Clin 1996; 14:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Findlay GH, Vismer HF. Black grain mycetoma. A study of the chemistry, formation and significance of the tissue grain in Madurella mycetomi infection. Br J Dermatol 1974; 91:297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ibrahim AI, El Hassan AM, Fahal A, van de Sande WW. A histopathological exploration of the Madurella mycetomatis grain. PLoS One 2013; 8:e57774.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jackson JA, Kaplan W, Kaufman L, Standard P. Development of fluorescent-antibody reagents for demonstration of Pseudallescheria boydii in tissues. J Clin Microbiol 1983; 18:668.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arastehfar A, Lim W, Daneshnia F, et al. Madurella real-time PCR, a novel approach for eumycetoma diagnosis. PLoS Negl Trop Dis 2020; 14:e0007845.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahmed SA, van den Ende BH, Fahal AH, et al. Rapid identification of black grain eumycetoma causative agents using rolling circle amplification. PLoS Negl Trop Dis 2014; 8:e3368.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lackner M, Najafzadeh MJ, Sun J, et al. Rapid identification of Pseudallescheria and Scedosporium strains by using rolling circle amplification. Appl Environ Microbiol 2012; 78:126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Negroni R, Tobón A, Bustamante B, et al. Posaconazole treatment of refractory eumycetoma and chromoblastomycosis. Rev Inst Med Trop Sao Paulo 2005; 47:339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Porte L, Khatibi S, Hajj LE, et al. Scedosporium apiospermum mycetoma with bone involvement successfully treated with voriconazole. Trans R Soc Trop Med Hyg 2006; 100:891.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loulergue P, Hot A, Dannaoui E, et al. Successful treatment of black-grain mycetoma with voriconazole. Am J Trop Med Hyg 2006; 75:1106.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gulati V, Bakare S, Tibrewal S, et al. A Rare Presentation of Concurrent Scedosporium apiospermum and Madurella grisea Eumycetoma in an Immunocompetent Host. Case Rep Pathol 2012; 2012:154201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lacroix C, de Kerviler E, Morel P, et al. Madurella mycetomatis mycetoma treated successfully with oral voriconazole. Br J Dermatol 2005; 152:1067.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oliveira Fde M, Unis G, Hochhegger B, Severo LC. Scedosporium apiospermum eumycetoma successfully treated with oral voriconazole: report of a case and review of the Brazilian reports on scedosporiosis. Rev Inst Med Trop Sao Paulo 2013; 55:121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kloezen W, Meis JF, Curfs-Breuker I, et al. In vitro antifungal activity of isavuconazole against Madurella mycetomatis. Antimicrob Agents Chemother 2012; 56:6054.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahmed SA, de Hoog GS, Stevens DA, et al. In vitro antifungal susceptibility of coelomycete agents of black grain eumycetoma to eight antifungals. Med Mycol 2015; 53:295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahmed SA, Kloezen W, Duncanson F, et al. Madurella mycetomatis is highly susceptible to ravuconazole. PLoS Negl Trop Dis 2014; 8:e2942.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Belkum A, Fahal AH, van de Sande WW. In vitro susceptibility of Madurella mycetomatis to posaconazole and terbinafine. Antimicrob Agents Chemother 2011; 55:1771.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van de Sande WW, Fahal AH, Bakker-Woudenberg IA, van Belkum A. Madurella mycetomatis is not susceptible to the echinocandin class of antifungal agents. Antimicrob Agents Chemother 2010; 54:2738.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fahal AH, Rahman IA, El-Hassan AM, et al. The safety and efficacy of itraconazole for the treatment of patients with eumycetoma due to Madurella mycetomatis. Trans R Soc Trop Med Hyg 2011; 105:127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother 2009; 53:24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sharma AM, Sharma N, Nat A, et al. Case report: Non-invasive management of Madura foot with oral posaconazole and ciprofloxacin. Am J Trop Med Hyg 2014; 91:1259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Difonzo EM, Massi D, Vanzi L, et al. Madurella mycetomatis mycetoma treated successfully with oral posaconazole. J Chemother 2011; 23:243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crabol Y, Poiree S, Bougnoux ME, et al. Last generation triazoles for imported eumycetoma in eleven consecutive adults. PLoS Negl Trop Dis 2014; 8:e3232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Troke P, Aguirrebengoa K, Arteaga C, et al. Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients. Antimicrob Agents Chemother 2008; 52:1743.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schaenman JM, DiGiulio DB, Mirels LF, et al. Scedosporium apiospermum soft tissue infection successfully treated with voriconazole: potential pitfalls in the transition from intravenous to oral therapy. J Clin Microbiol 2005; 43:973.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muñoz P, Marín M, Tornero P, et al. Successful outcome of Scedosporium apiospermum disseminated infection treated with voriconazole in a patient receiving corticosteroid therapy. Clin Infect Dis 2000; 31:1499.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lexier R, Walmsley SL. Successful treatment of Madura foot caused by Pseudallescheria boydii with Escherichia coli superinfection: a case report. Can J Surg 1999; 42:307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turner PG. Madura foot or plantar fibromatosis. J Bone Joint Surg Br 1989; 71:531.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van de Sande W, Fahal A, Ahmed SA, et al. Closing the mycetoma knowledge gap. Med Mycol 2018; 56:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suleiman SH, Wadaella el S, Fahal AH. The Surgical Treatment of Mycetoma. PLoS Negl Trop Dis 2016; 10:e0004690.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Welsh O. Mycetoma. Current concepts in treatment. Int J Dermatol 1991; 30:387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahgoub ES. Mycetoma. Semin Dermatol 1985; 4:230.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wadal A, Elhassan TA, Zein HA, et al. Predictors of Post-operative Mycetoma Recurrence Using Machine-Learning Algorithms: The Mycetoma Research Center Experience. PLoS Negl Trop Dis 2016; 10:e0005007.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gismalla MDA, Ahmed GMA, MohamedAli MM, et al. Surgical management of eumycetoma: experience from Gezira Mycetoma Center, Sudan. Trop Med Health 2019; 47:6.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 2439 Version 23.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26738840" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Mycetoma: a unique neglected tropical disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26738840" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Mycetoma: a unique neglected tropical disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25816316" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Mycetoma in the Sudan: an update from the Mycetoma Research Centre, University of Khartoum, Sudan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3354772" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Mycetoma in the Republic of Niger: clinical features and epidemiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24451559" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : [Mycetomas diagnosed in Senegal from 2008 to 2010].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Mycétomes en Mauritanie, espèces rencontrées, caractèresépidémiologiques et répartition dans le pays. A propos de 122 cas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13299347" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Mycetoma in the Sudan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8333574" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Mycetomas in northern Yemen: identification of causative organisms and epidemiologic considerations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7722053" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Mycetoma caused by Acremonium falciforme: successful treatment with itraconazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7650573" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : The host tissue reaction to Madurella mycetomatis: new classification.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17644456" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Melanin biosynthesis in Madurella mycetomatis and its effect on susceptibility to itraconazole and ketoconazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26332238" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : A Polymorphism in the Chitotriosidase Gene Associated with Risk of Mycetoma Due to Madurella mycetomatis Mycetoma--A Retrospective Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17709521" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Polymorphisms in genes involved in innate immunity predispose toward mycetoma susceptibility.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8559188" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Mycetoma due to Exophiala jeanselmei and Mycobacterium chelonae in a 73-year-old man with idiopathic CD4+ T lymphocytopenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11168668" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Madurella infection in an immunocompromised host.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17097407" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Acremonium mycetoma in a heart transplant recipient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11429018" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Atypical presentation of Madurella mycetomatis mycetoma in a renal transplant patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11792997" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Madura foot in the U.K.: fungal osteomyelitis after renal transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6347091" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Acremonium falciforme (Cephalosporium falciforme) mycetoma in a renal transplant patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1474458" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Mycetoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/579331" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Immunological status of mycetoma patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27434108" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Th-1, Th-2 Cytokines Profile among Madurella mycetomatis Eumycetoma Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3550122" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Mycetoma in Saudi Arabia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17005754" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Phaeoacremonium krajdenii, a cause of white grain eumycetoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20701685" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Mycetoma caused by Phaeoacremonium parasiticum--a case confirmed with B-tubulin sequence analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22205798" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : New species of Madurella, causative agents of black-grain mycetoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Mycetoma in Iran: study of 62 cases
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21781209" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Eumycetoma caused by Diaporthe phaseolorum (Phomopsis phaseoli): a case report and a mini-review of Diaporthe/Phomopsis spp invasive infections in humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22760037" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Pleurostomophora ochracea, a novel agent of human eumycetoma with yellow grains.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19659864" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Paecilomyces lilacinus eumycetoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24432236" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Fusarium subglutinans: A new eumycetoma agent.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27076666" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Novel Taxa Associated with Human Fungal Black-Grain Mycetomas: Emarellia grisea gen. nov., sp. nov., and Emarellia paragrisea sp. nov.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25737597" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Revision of agents of black-grain eumycetoma in the order Pleosporales.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27928841" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Fusarium species causing eumycetoma: Report of two cases and comprehensive review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27224667" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Phaeoacremonium sphinctrophorum as a Novel Agent of Eumycetoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29263207" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Nigrograna mackinnonii, Not Trematosphaeria grisea (syn., Madurella grisea), Is the Main Agent of Black Grain Eumycetoma in Latin America.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24244780" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Global burden of human mycetoma: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6686344" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : An ultrastructural study of pale eumycetoma grains.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32730340" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : The genus Madurella: Molecular identification and epidemiology in Sudan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19923486" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Phenotypic and molecular characterization of Madurella pseudomycetomatis sp. nov., a novel opportunistic fungus possibly causing black-grain mycetoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9988489" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Nocardia, nocardiosis and mycetoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13933056" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : [On the geographic distribution and incidence of mycetoma agents].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13933056" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : [On the geographic distribution and incidence of mycetoma agents].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13933056" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : [On the geographic distribution and incidence of mycetoma agents].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32233084" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Diagnostic implications of mycetoma derived from Madurella pseudomycetomatis isolates from Mexico.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4640043" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : The frequent isolation of Phialophora verrucosa and Phialophora pedrosoi from natural sources.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11880433" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Environmental occurrence of Madurella mycetomatis, the major agent of human eumycetoma in Sudan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5755457" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : [Research on the presence of agents of mycetoma in the soil and thorny plants of Senegal and Mauritania].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5070631" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : [Epidemiology of mycetomas].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12225511" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Epidemiological aspects of mycetoma from a retrospective study of 264 cases in West Bengal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12225511" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Epidemiological aspects of mycetoma from a retrospective study of 264 cases in West Bengal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1308000" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : [Epidemiology of mycetoma in Mexico: study of 2105 cases].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10840369" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Mycetoma - an unusual site.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10717567" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : [Tumoral mycetoma of the buttock].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1171632" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Tumor of the mandible caused by Madurella mycetomil.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9063356" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Intraspinal mycetoma: report of two cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9692156" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Cystic mycetoma: an unusual clinical presentation of Madurella mycetomatis infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5065467" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Lymph node involvement in mycetoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33406268" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Multiple extensive Madurella mycetomatis eumycetoma lesions: a case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8366881" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Mycetoma: a retrospective study of 41 cases seen in São Paulo, Brazil, from 1978 to 1989.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28957324" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Broncho-pleuro-cutaneous fistula and pneumothorax: Rare challenging complications of chest wall eumycetoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27711109" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Mycetoma Pulmonary Secondaries from a Gluteal Eumycetoma: An Unusual Presentation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27442512" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Multiple Mycetoma Lung Secondaries from Knee Eumycetoma: An Unusual Complication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27490198" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Madurella mycetomatis-Induced Massive Shoulder Joint Destruction: A Management Challenge.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9508332" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Unexpected high prevalence of secondary bacterial infection in patients with mycetoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18540305" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Cytodiagnosis of eumycotic mycetoma: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31465459" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : The Accuracy of Histopathological and Cytopathological Techniques in the Identification of the Mycetoma Causative Agents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33537774" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Mycetoma imaging: the best practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9278658" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Ultrasonographic imaging of mycetoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11167327" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : MR and other imaging methods in the investigation of mycetomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17369726" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Radiological manifestations of madura foot in the Eastern Province of Saudi Arabia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15307432" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Pathological fractures in mycetoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11913759" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Mycetoma caused by Fusarium solani with osteolytic lesions on the hand: case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22981317" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : New MRI grading system for the diagnosis and management of mycetoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12605286" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : MRI of mycetoma of the foot: two cases demonstrating the dot-in-circle sign.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8821162" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Mycetoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4139964" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Black grain mycetoma. A study of the chemistry, formation and significance of the tissue grain in Madurella mycetomi infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23483927" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : A histopathological exploration of the Madurella mycetomatis grain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6195179" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Development of fluorescent-antibody reagents for demonstration of Pseudallescheria boydii in tissues.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31940343" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Madurella real-time PCR, a novel approach for eumycetoma diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25474355" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Rapid identification of black grain eumycetoma causative agents using rolling circle amplification.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22057865" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Rapid identification of Pseudallescheria and Scedosporium strains by using rolling circle amplification.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16553324" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Posaconazole treatment of refractory eumycetoma and chromoblastomycosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16714039" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Scedosporium apiospermum mycetoma with bone involvement successfully treated with voriconazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17172376" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Successful treatment of black-grain mycetoma with voriconazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23133772" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : A Rare Presentation of Concurrent Scedosporium apiospermum and Madurella grisea Eumycetoma in an Immunocompetent Host.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15888176" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Madurella mycetomatis mycetoma treated successfully with oral voriconazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23563766" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Scedosporium apiospermum eumycetoma successfully treated with oral voriconazole: report of a case and review of the Brazilian reports on scedosporiosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22964246" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : In vitro antifungal activity of isavuconazole against Madurella mycetomatis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25631481" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : In vitro antifungal susceptibility of coelomycete agents of black grain eumycetoma to eight antifungals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24945848" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Madurella mycetomatis is highly susceptible to ravuconazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21263050" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : In vitro susceptibility of Madurella mycetomatis to posaconazole and terbinafine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20350944" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Madurella mycetomatis is not susceptible to the echinocandin class of antifungal agents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21247608" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : The safety and efficacy of itraconazole for the treatment of patients with eumycetoma due to Madurella mycetomatis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18955533" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Antifungal therapeutic drug monitoring: established and emerging indications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25349373" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Case report: Non-invasive management of Madura foot with oral posaconazole and ciprofloxacin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21803706" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Madurella mycetomatis mycetoma treated successfully with oral posaconazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25299610" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Last generation triazoles for imported eumycetoma in eleven consecutive adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18212110" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15695722" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Scedosporium apiospermum soft tissue infection successfully treated with voriconazole: potential pitfalls in the transition from intravenous to oral therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11096022" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Successful outcome of Scedosporium apiospermum disseminated infection treated with voriconazole in a patient receiving corticosteroid therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10459334" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Successful treatment of Madura foot caused by Pseudallescheria boydii with Escherichia coli superinfection: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2722952" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Madura foot or plantar fibromatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28992217" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Closing the mycetoma knowledge gap.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27336736" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : The Surgical Treatment of Mycetoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1894401" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Mycetoma. Current concepts in treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Mycetoma
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27798643" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Predictors of Post-operative Mycetoma Recurrence Using Machine-Learning Algorithms: The Mycetoma Research Center Experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30675125" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Surgical management of eumycetoma: experience from Gezira Mycetoma Center, Sudan.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
